Tim Clackson, Theseus Pharmaceuticals CEO
November 27, 2023 07:11 AM EST
Deals

Tang’s Con­cen­tra faces off with Fore­site, Or­biMed in buy­out bat­tle for strug­gling biotech The­seus

Ayisha Sharma

News Reporter

Cal­i­for­nia in­vest­ment group Tang Cap­i­tal Man­age­ment is con­tin­u­ing its streak of buy­out of­fers for strug­gling biotechs, this time eye­ing The­seus Phar­ma­ceu­ti­cals. How­ev­er, an al­ter­na­tive propo­si­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times